Clinical Trial Update: Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

This document reports results from a Phase 1/2 clinical trial evaluating fludarabine, rituximab, and lenalidomide in minimally treated or untreated chronic lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Fludarabine (Fludarabine)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-05-04